发布求助
文献互助 智能选刊 最新文献

CNS Oncology最新文献

筛选
英文 中文
Factors associated with delayed diagnosis among Filipino pediatric brain tumor patients: a retrospective review 菲律宾儿童脑肿瘤患者延迟诊断的相关因素:一项回顾性回顾
CNS Oncology Pub Date : 2022-06-09 DOI: 10.2217/cns-2022-0009
P. Orduña, Cheryl Anne P Lubaton-Sacro
{"title":"Factors associated with delayed diagnosis among Filipino pediatric brain tumor patients: a retrospective review","authors":"P. Orduña, Cheryl Anne P Lubaton-Sacro","doi":"10.2217/cns-2022-0009","DOIUrl":"https://doi.org/10.2217/cns-2022-0009","url":null,"abstract":"Aim: Determine delayed diagnosis measured by prediagnostic symptomatic interval (PSI) among Filipino pediatric brain tumor patients and identify associated factors. Methods: Data was collected retrospectively on Philippine General Hospital pediatric brain tumor patients from 2015 to 2019. PSI was calculated. Associated factors were determined. Results: 196 patients were included. Median PSI was 80.5 days. Longer PSI was significantly associated with older age, supratentorial and low-grade tumors, more physician consults prior to subspecialist referral, longer interval from neuroimaging request to facilitation, and those presenting with seizures (11-month delay), poor school performance (1-year delay), behavioral changes (1.3-year delay) and secondary amenorrhea (3-year delay). Conclusion: Delayed diagnosis among Filipino brain tumor patients is associated with age, tumor characteristics and symptoms that are uncommon in this condition. Awareness of these symptoms through physician education, close monitoring of patients, early subspecialist referral and better neuroimaging access may lead to earlier diagnosis.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81652989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Large mirror brain metastases from primary undifferentiated sarcoma of the breast: case report and review of the literature. 乳房原发未分化肉瘤的大镜像脑转移:病例报告及文献回顾。
CNS Oncology Pub Date : 2022-06-01 DOI: 10.2217/cns-2022-0001
Nuno Cubas Farinha, Wilson Teixeira, Diogo Roque, Sergio Livraghi
{"title":"Large mirror brain metastases from primary undifferentiated sarcoma of the breast: case report and review of the literature.","authors":"Nuno Cubas Farinha,&nbsp;Wilson Teixeira,&nbsp;Diogo Roque,&nbsp;Sergio Livraghi","doi":"10.2217/cns-2022-0001","DOIUrl":"https://doi.org/10.2217/cns-2022-0001","url":null,"abstract":"<p><p>Primary breast sarcomas are rare high-grade tumors with a reported incidence of <1% of breast malignancies. Its dissemination to the CNS is exceptional and only one is found in the literature. The authors described the case of a 22-year-old female with history of a breast undifferentiated sarcoma that present with two large bilateral retrolenticular brain metastases. Both lesions were excised in the same procedure and she underwent adjuvant therapy. She died 24 months after surgery. Despite being aggressive lesions, aggressive treatment of primary breast sarcomas including brain metastases excision, should be considered in order to improve overall survival.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/f9/cns-11-85.PMC9134969.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10241190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life. 胶质瘤幸存者的日常功能：与认知功能、心理因素和生活质量的关系。
CNS Oncology Pub Date : 2022-06-01 Epub Date: 2022-05-18 DOI: 10.2217/cns-2022-0002
Kathleen Van Dyk, Lucy Wall, Brandon F Heimberg, Justin Choi, Catalina Raymond, Chencai Wang, Albert Lai, Timothy F Cloughesy, Benjamin M Ellingson, Phioanh Nghiemphu
{"title":"Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life.","authors":"Kathleen Van Dyk, Lucy Wall, Brandon F Heimberg, Justin Choi, Catalina Raymond, Chencai Wang, Albert Lai, Timothy F Cloughesy, Benjamin M Ellingson, Phioanh Nghiemphu","doi":"10.2217/cns-2022-0002","DOIUrl":"10.2217/cns-2022-0002","url":null,"abstract":"<p><p><b>Aim:</b> Understanding and supporting quality of life (QoL) and daily functioning in glioma patients is a clinical imperative. In this study, we examined the relationship between cognition, psychological factors, measures of health-related QoL and functioning in glioma survivors. <b>Materials & methods:</b> We examined neuropsychological, self-reported cognition, mood and QoL correlates of work and non-work-related daily functioning in 23 glioma survivors, and carried out linear models of the best predictors. <b>Results & conclusion:</b> A total of 13/23 participants were working at the time of enrollment. The best model for worse work-related functioning (R<sup>2</sup> = .83) included worse self-reported cognitive function, depression, loneliness and brain tumor symptoms. The best model for worse non-work-related functioning (R<sup>2</sup> = .61) included worse self-reported cognitive functioning, anxiety, sleep disturbance and physical functioning. Neuropsychological variables were not among the most highly correlated with function. Worse cognitive, particularly self-reported and psychosocial outcomes may compromise optimal functioning in glioma survivors.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/22/11/cns-11-84.PMC9134930.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9970553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review. 治疗胶质母细胞瘤的放疗-药物组合：简要回顾。
CNS Oncology Pub Date : 2022-06-01 Epub Date: 2022-05-23 DOI: 10.2217/cns-2021-0015
Patrick G McAleavey, Gerard M Walls, Anthony J Chalmers
{"title":"Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.","authors":"Patrick G McAleavey, Gerard M Walls, Anthony J Chalmers","doi":"10.2217/cns-2021-0015","DOIUrl":"10.2217/cns-2021-0015","url":null,"abstract":"<p><p>Glioblastoma (GBM) accounts for over 50% of gliomas and carries the worst prognosis of all solid tumors. Owing to the limited local control afforded by surgery alone, efficacious adjuvant treatments such as radiotherapy (RT) and chemotherapy are fundamental in achieving durable disease control. The best clinical outcomes are achieved with tri-modality treatment consisting of surgery, RT and systemic therapy. While RT-chemotherapy combination regimens are well established in oncology, this approach was largely unsuccessful in GBM until the introduction of temozolomide. The success of this combination has stimulated the search for other candidate drugs for concomitant use with RT in GBM. This review seeks to collate the current evidence for these agents and synthesize possible future directions for the field.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134931/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74497824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. 口服 p-STAT3 抑制剂 WP1066 治疗复发性恶性胶质瘤患者的首次人体 I 期试验。
CNS Oncology Pub Date : 2022-06-01 Epub Date: 2022-05-16 DOI: 10.2217/cns-2022-0005
John de Groot, Martina Ott, Jun Wei, Cynthia Kassab, Dexing Fang, Hinda Najem, Barbara O'Brien, Shiao-Pei Weathers, Carlos Kamiya Matsouka, Nazanin K Majd, Rebecca A Harrison, Gregory N Fuller, Jason T Huse, James P Long, Raymond Sawaya, Ganesh Rao, Tobey J MacDonald, Waldemar Priebe, Michael DeCuypere, Amy B Heimberger
{"title":"A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma.","authors":"John de Groot, Martina Ott, Jun Wei, Cynthia Kassab, Dexing Fang, Hinda Najem, Barbara O'Brien, Shiao-Pei Weathers, Carlos Kamiya Matsouka, Nazanin K Majd, Rebecca A Harrison, Gregory N Fuller, Jason T Huse, James P Long, Raymond Sawaya, Ganesh Rao, Tobey J MacDonald, Waldemar Priebe, Michael DeCuypere, Amy B Heimberger","doi":"10.2217/cns-2022-0005","DOIUrl":"10.2217/cns-2022-0005","url":null,"abstract":"<p><p><b>Aim:</b> To ascertain the maximum tolerated dose (MTD)/maximum feasible dose (MFD) of WP1066 and p-STAT3 target engagement within recurrent glioblastoma (GBM) patients. <b>Patients & methods:</b> In a first-in-human open-label, single-center, single-arm 3 + 3 design Phase I clinical trial, eight patients were treated with WP1066 until disease progression or unacceptable toxicities. <b>Results:</b> In the absence of significant toxicity, the MFD was identified to be 8 mg/kg. The most common adverse event was grade 1 nausea and diarrhea in 50% of patients. No treatment-related deaths occurred; 6 of 8 patients died from disease progression and one was lost to follow-up. Of 8 patients with radiographic follow-up, all had progressive disease. The longest response duration exceeded 3.25 months. The median progression-free survival (PFS) time was 2.3 months (95% CI: 1.7 months-NA months), and 6-month PFS (PFS6) rate was 0%. The median overall survival (OS) rate was 25 months (95% CI: 22.5 months-NA months), with an estimated 1-year OS rate of 100%. Pharmacokinetic (PK) data demonstrated that at 8 mg/kg, the T<sub>1/2</sub> was 2-3 h with a dose dependent increase in the C<sub>max</sub>. Immune monitoring of the peripheral blood demonstrated that there was p-STAT3 suppression starting at a dose of 1 mg/kg. <b>Conclusion:</b> Immune analyses indicated that WP1066 inhibited systemic immune p-STAT3. WP1066 had an MFD identified at 8 mg/kg which is the target allometric dose based on prior preclinical modeling in combination with radiation therapy and a Phase II study is being planned for newly diagnosed MGMT promoter unmethylated glioblastoma patients.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82007685","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Insight about the characteristics and surgical resectability of adult pilocytic astrocytoma: tertiary center experience. 洞察成人柔毛细胞星形细胞瘤的特点和手术切除可能性：三级中心的经验。
CNS Oncology Pub Date : 2022-04-06 DOI: 10.2217/cns-2021-0014
Baha'eddin A Muhsen, Abdelmajid I Aljariri, Maher Elayyan, Hawazen Hirbawi, Mahmoud A Masri
{"title":"Insight about the characteristics and surgical resectability of adult pilocytic astrocytoma: tertiary center experience.","authors":"Baha'eddin A Muhsen, Abdelmajid I Aljariri, Maher Elayyan, Hawazen Hirbawi, Mahmoud A Masri","doi":"10.2217/cns-2021-0014","DOIUrl":"10.2217/cns-2021-0014","url":null,"abstract":"<p><p><b>Aim:</b> Adult pilocytic astrocytoma is a rare tumor. We aim to contribute to understanding its clinical course and prognosis. <b>Patients & methods:</b> We searched our database for patients older than 18 years with pathology-proven pilocytic astrocytoma. Patients' clinical data were analyzed. <b>Results:</b> Fifteen patients were identified. The median age at diagnosis was 25 years (range: 18-56). Tumors were supratentorial in 47%. Gross-total and near-total resections were achieved in 40%, and sub-total resection in 47%. One (7%) recurrence and no mortality were encountered during a median follow-up of 11 months (range: 1-76). <b>Conclusion:</b> Pilocytic astrocytoma behaves differently in adults compared with pediatrics. It tends to arise in surgically challenging areas where the extent of resection may be limited. Total resection should be the main therapy whenever feasible. The survival rates are good, and recurrence is low.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8988253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90973840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Systemic inflammatory biomarkers in primary central nervous system lymphoma versus high-grade glioma: exploratory, comparative and correlative analysis 原发性中枢神经系统淋巴瘤与高级别胶质瘤的系统性炎症生物标志物:探索性、比较性和相关性分析
CNS Oncology Pub Date : 2022-04-04 DOI: 10.2217/cns-2022-0004
T. Gupta, P. Nayak, Y. Baviskar, Meetakshi Gupta, A. Moiyadi, S. Epari, A. Janu, N. Purandare, V. Rangarajan, B. Bagal, Abhishek Chatterjee, G. Sastri
{"title":"Systemic inflammatory biomarkers in primary central nervous system lymphoma versus high-grade glioma: exploratory, comparative and correlative analysis","authors":"T. Gupta, P. Nayak, Y. Baviskar, Meetakshi Gupta, A. Moiyadi, S. Epari, A. Janu, N. Purandare, V. Rangarajan, B. Bagal, Abhishek Chatterjee, G. Sastri","doi":"10.2217/cns-2022-0004","DOIUrl":"https://doi.org/10.2217/cns-2022-0004","url":null,"abstract":"Aim: To assess systemic inflammatory biomarkers in non invasive differential diagnosis of primary central nervous system lymphoma (PCNSL) from high-grade glioma (HGG). Materials & methods: Patients with similar morphology (PCNSL or HGG) on conventional neuro-imaging were included. Systemic inflammatory indices were calculated from pretreatment complete blood counts and liver function tests and compared against histopathology as reference standard. Results: Mean values of absolute lymphocyte count and prognostic nutritional index were significantly different between PCNSL (n = 42) versus HGG (n = 16). Area under receiver operating characteristics curve for absolute lymphocyte count and prognostic nutritional index in the diagnosis of PCNSL was 0.70 and 0.72 respectively suggesting fair and acceptable diagnostic accuracy. Conclusion: Systemic inflammatory biomarkers complement established clinico-radiological features and aid in the differential diagnosis of PCNSL from HGG.","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86789680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch. 影像学解释预测少突胶质瘤分级的挑战:来自神经肿瘤科的一份报告。
CNS Oncology Pub Date : 2022-03-01 Epub Date: 2022-02-10 DOI: 10.2217/cns-2021-0005
Orwa Aboud, Ritu Shah, Elizabeth Vera, Eric Burton, Brett Theeler, Jing Wu, Lisa Boris, Martha Quezado, Jennifer Reyes, Kathleen Wall, Mark R Gilbert, Terri S Armstrong, Marta Penas-Prado
{"title":"Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch.","authors":"Orwa Aboud,&nbsp;Ritu Shah,&nbsp;Elizabeth Vera,&nbsp;Eric Burton,&nbsp;Brett Theeler,&nbsp;Jing Wu,&nbsp;Lisa Boris,&nbsp;Martha Quezado,&nbsp;Jennifer Reyes,&nbsp;Kathleen Wall,&nbsp;Mark R Gilbert,&nbsp;Terri S Armstrong,&nbsp;Marta Penas-Prado","doi":"10.2217/cns-2021-0005","DOIUrl":"https://doi.org/10.2217/cns-2021-0005","url":null,"abstract":"<p><p><b>Background:</b> To illustrate challenges of imaging interpretation in patients with oligodendroglioma seen at a referral center and evaluate interrater reliability. <b>Methods:</b> Two neuro-oncologists reviewed diagnostic preradiation MRIs of oligodendroglioma patients; interrater reliability was calculated with the kappa coefficient (k). A neuroradiologist measured presurgical apparent diffusion coefficient (ADC), if available. <b>Results:</b> Extensive enhancement was noted in four of 58 patients, k = 0.7; necrosis in seven of 58, k = 0.61; calcification in seven of 17, k = 1.0; diffusion restriction in two of 39 patients, k = 1.0 (all only in grade 3). ADC values with receiver operator characteristic analysis for area under the curve were 0.473, not significantly different from the null hypothesis (p = 0.14). <b>Conclusions:</b> Extensive enhancement, necrosis and calcification correlated with grade 3 oligodendroglioma in our sample. However, interrater variability is an important limitation when assessing radiographic features, supporting the need for standardization of imaging protocols and their interpretation.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/16/3e/cns-11-83.PMC8988255.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39906197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Prolonged response of recurrent IDH-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab. 复发性idh野生型胶质母细胞瘤对派姆单抗激光间质热治疗的延长反应
CNS Oncology Pub Date : 2022-03-01 DOI: 10.2217/cns-2021-0013
Helen Hwang, Jiayi Huang, Karam Khaddour, Omar H Butt, George Ansstas, Jie Chen, Ruth Gn Katumba, Albert H Kim, Eric C Leuthardt, Jian L Campian
{"title":"Prolonged response of recurrent <i>IDH</i>-wild-type glioblastoma to laser interstitial thermal therapy with pembrolizumab.","authors":"Helen Hwang,&nbsp;Jiayi Huang,&nbsp;Karam Khaddour,&nbsp;Omar H Butt,&nbsp;George Ansstas,&nbsp;Jie Chen,&nbsp;Ruth Gn Katumba,&nbsp;Albert H Kim,&nbsp;Eric C Leuthardt,&nbsp;Jian L Campian","doi":"10.2217/cns-2021-0013","DOIUrl":"https://doi.org/10.2217/cns-2021-0013","url":null,"abstract":"<p><p>Despite the improved understanding of the molecular and genetic heterogeneity of glioblastoma, there is still an unmet need for better therapeutics, as treatment approaches have remained unchanged in recent years. Research into the role of the immune microenvironment has generated enthusiasm for testing immunotherapy (specifically, immune checkpoint inhibitors). However, to date, trials of immunotherapy in glioblastoma have not demonstrated a survival advantage. Combination approaches aimed at optimally inducing response to immune checkpoint inhibitors with radiotherapy are currently being investigated. Herein, the authors describe their experience of the potential benefit and clinical outcomes of using combination pembrolizumab (an immune checkpoint inhibitor) and laser interstitial thermal therapy in a case series of patients with recurrent <i>IDH</i>-wild-type glioblastoma.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/8e/cns-11-81.PMC8988254.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9583438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
Multi-joint steroid-induced avascular necrosis in a malignant brain tumor patient. 恶性脑肿瘤患者多关节类固醇诱导的缺血性坏死。
CNS Oncology Pub Date : 2021-12-01 Epub Date: 2021-10-12 DOI: 10.2217/cns-2021-0006
Jessica M Lewis-Gonzalez, Mallika P Patel, Katherine B Peters
{"title":"Multi-joint steroid-induced avascular necrosis in a malignant brain tumor patient.","authors":"Jessica M Lewis-Gonzalez,&nbsp;Mallika P Patel,&nbsp;Katherine B Peters","doi":"10.2217/cns-2021-0006","DOIUrl":"https://doi.org/10.2217/cns-2021-0006","url":null,"abstract":"<p><p>Avascular necrosis (AVN) is a rare but serious adverse event associated with the use of corticosteroids for long durations or at high doses. This case report describes a 47-year-old female patient with low-grade astrocytoma who was initiated on low-dose dexamethasone for symptom management. The patient developed joint pain 1 year after steroid exposure, then was found to have AVN of the hip followed by multiple other joints. This case report highlights the extent to which AVN can occur in patients with brain tumors following a short course of low-dose corticosteroids. Careful evaluation of and monitoring for the development of AVN should occur frequently in patients with brain tumors given the frequent use of corticosteroids for symptom management in this population.</p>","PeriodicalId":10469,"journal":{"name":"CNS Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/62/cns-10-78.PMC8610003.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39508362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信